Call toll-free 800.328.1267
Merck has struggled for most of the year, and now some traders may look for another push to the downside. The first pattern on today’s chart is the series of higher lows from mid-November through early last week. MRK has dropped below that line, which may be viewed as...
Johnson & Johnson doesn't move quickly, but options traders may see ways to make it interesting. The pharmaceutical company has formed some potentially bullish patterns since July 17, when it rallied on strong quarterly results. First, the stock advanced from...
Stocks are pulling back as traders wait for key inflation data and the start of earnings season. The S&P 500 fell 1.5 percent in the holiday-shortened period between Friday, December 29, and Friday, January 5. It was the first drop in 10 weeks, ending the index's...
Merck surged in late 2022 and consolidated during the first quarter. Now the drug maker could be breaking out. The first pattern on today’s chart is the rally between mid-October and early January, which included a breakout to new record highs. MRK then pulled back...
Diabetes company DexCom has been fighting higher since June, and now it may be interesting to trend followers. The first pattern on today’s chart is the pair of bullish gaps last month. The initial rally came after the Centers for Medicare and Medicaid Services...
Something new happened in the stock market yesterday following a month of steady gains: some names are breaking out. Twenty three members of the S&P 500 made new 52-week highs on Monday. That was the most since April 21, according to TradeStation data. Six of...
Stocks advanced again last week as inflation-wary investors keep inching back into the market. The S&P 500 rose 0.36 percent between Friday, July 29, and Friday, August 5. It was the third straight weekly advance, returning the index to its highest level in two...
United Therapeutics spent more than a year consolidating around its 2015 highs. Now the biotech may be attempting a breakout. Notice the surge to new all-time highs late last month. The rally followed news that the Food & Drug Administration approved its Tyvaso...
Biotechnology stocks have pulled back dramatically, but positive news has been growing as the sector tries to stabilize at a historic level. Positive news has emerged on several companies in the industry, including takeovers, regulatory approvals and drug-trial data....